
CLAIMS

1. A pharmaceutical composition for treating pigmented villonodular synovitis (PVNS), tenosynovial giant cell tumor (TGCT), plexiform neurofibromas, or malignant peripheral nerve sheath tumors (MPNST) in a subject, said pharmaceutical composition comprising a compound having the formula:



or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable diluent or carrier;
wherein if the subject suffers from MPNST, the pharmaceutical composition is for administration in combination with sirolimus.

2. The pharmaceutical composition according to claim 1, wherein the subject suffers from pigmented villonodular synovitis (PVNS) or tenosynovial giant cell tumor (TGCT).

3. The pharmaceutical composition of claim 1, wherein the subject suffers from TGCT.

4. The pharmaceutical composition of claim 1, wherein the subject suffers from PVNS.

5. The pharmaceutical composition of claim 1, wherein the subject suffers from metastasis of TGCT.


6. The pharmaceutical composition of claim 1, wherein the subject suffers from metastasis of PNVS.

7. The pharmaceutical composition according to claim 1, wherein the subject suffers from plexiform neurofibromas.

8. The pharmaceutical composition of claim 1, wherein the subject suffers from malignant peripheral nerve sheath tumors (MPNST).

9. The pharmaceutical composition of any one of claims 1 to 8, wherein the pharmaceutical composition is formulated for oral administration.

10. Use of a compound having the formula:



or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of pigmented villonodular synovitis (PVNS), tenosynovial giant cell tumor (TGCT), plexiform neurofibromas, or malignant peripheral nerve sheath tumors (MPNST) in a subject; wherein if the subject suffers from MPNST, the medicament is for administration in combination with sirolimus.

11. The use according to claim 10, wherein the subject suffers from pigmented villonodular synovitis (PVNS) or tenosynovial giant cell tumor (TGCT).

12. The use of claim 10, wherein the subject suffers from TGCT.

13. The use of claim 10, wherein the subject suffers from PVNS.

14. The use of claim 10, wherein the subject suffers from metastasis of TGCT.

15. The use of claim 10, wherein the subject suffers from metastasis of PNVS.

16. The use according to claim 10, wherein the subject suffers from plexiform neurofibromas.

17. The use of claim 10, wherein the subject suffers from malignant peripheral nerve sheath tumors (MPNST).

18. The use of any one of claims 10 to 17, wherein the medicament is formulated for oral administration.